Zolgensma® (onasemnogene abeparvovec) is conditionally approved in Europe for the treatment of patients with spinal muscular atrophy (SMA) and a clinical diagnosis of SMA Type 1; or SMA patients with up to three copies of the SMN2 gene Zolgensma has de…
New Kisqali® (ribociclib)* overall survival subgroup analysis in HR+/HER2- advanced breast cancer (ABC) and additional Piqray® (alpelisib) data in patients in HR+/HER2- ABC patients with a PIK3CA mutationResults from five-year adjuvant treatment study …
It was the early ’90s, and a medical student in Caracas, Venezuela, named Florencia Segal was attending rounds at a state hospital as part of her training. She was struck by the number of patients with opportunistic infections due to acquired immunodef…
Gervais Tougas never thought he’d have to face this again. In 2003, while serving as a division head in one of McMaster University’s teaching hospitals, a SARS outbreak in nearby Toronto, Canada tossed his organization into uncharted waters. Like its c…
Tabrecta (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic NSCLC with a mutation that leads to MET exon 14 skipping (METex14)1 ~4,000-5,000 patients are diagnosed with METex14 metastatic …
Members of the global research community have joined forces in unconventional configurations to defeat the COVID-19 pandemic. And they’re working faster than ever before to find solutions.A new clinical trial illustrates how quickly teams are assemblin…
CHMP positive opinion advances efforts to provide first-in-class LABA/LAMA/ICS combination for patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment in the EU. Digital companion with app and sensor that provide inhalation conf…
A fast-paced Novartis joint development project with one of the world’s largest technology companies has created an innovative, AI-enabled digital nurse to support heart failure patients in China.Co-developed with China’s internet multinational Tencent…
Cosentyx® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) disease spectrum There are approximately 1.7 million …
Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of s…